Treatment

The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.

The Department of Health and Human Services today issued a notice of public rulemaking to improve the exchange of patient records used in the treatment of substance use disorder. HHS proposes provisions to implement section 3221 of the Coronavirus Aid, Relief, and Economic Security Act to ensure providers have more complete and timely information when treating patients with SUD, including updating patient consent requirements and aligning disclosure requirements with those under HIPAA regulations. AHA is among a host of organizations who have pushed for such changes, including one which would enable providers to get a patient’s consent just once to share substance use records for treatment and health care operations. HHS will accept comments for the next 60 days.

This webinar provided RCORP grantees with the tools to complete a disparities impact statement, to support efforts to address populations in rural communities that have historically suffered from poorer health outcomes and health inequities as a part of the prevention, treatment, and recovery of SUD/OUD.

Last week, the Secretary of the U.S. Department of Health & Human Services (HHS) made this declaration for Florida, South Carolina, and Puerto Rico after determining that the devastation of Hurricane Iain required urgent response from the federal government

On March 16, 2020, to facilitate access to methadone treatment from opioid treatment programs (OTPs) during the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration allowed states to request blanket exceptions to provide up to 28 and 14 days of take-home methadone for stable and less stable patients, respectively; this signaled a shift in practice because most patients historically receive methadone daily from OTPs.

Researchers looked at survey responses from women of reproductive age across eight rural U.S. regions to determine the association between contraceptive use and SUD treatment, healthcare utilization, and substance use.

This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).

As substance use and its progression to impairment, loss of control, and development of substance use disorders is a significant problem for adolescents and young adults, this presentation will provide a more in-depth review of developmentally informed approaches to engaging youth and their families in treatment. In this Part 2, the presentation will provide details on treatment options and developmentally informed approaches to engaging youth and their families in treatment.

Advancing health equity involves ensuring that everyone has a fair and just opportunity to be as healthy as possible. This also applies to behavioral health. In conjunction with quality services, this involves addressing social determinants, such as employment and housing stability, insurance status, proximity to services, culturally responsive care – all of which have an impact on behavioral health outcomes.

This session had three presenters who covered contingency management, prevention of stimulant use for children, and peer support.